# Integer Holdings Corp: Form 10-Q for the period ended Sep 28, 2012

- Company: [Integer Holdings Corp](/companies/itgr.md) (CIK 1114483)
- Form: 10-Q
- Filed: 2012-11-06
- Accepted by EDGAR: Nov 6, 2012, 20:50 ET
- Period: 2012-09-28
- Accession: 0001193125-12-454418
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/1114483/000119312512454418/d435929d10q.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/1114483/000119312512454418/

## Figures reported in this filing

Standardized XBRL line items for the period ended 2012-09-28.

| Line item | Period | Value | XBRL concept |
| --- | --- | ---: | --- |
| Revenue | 3 months, 2012-06-30 to 2012-09-28 | $161.3m | us-gaap:SalesRevenueNet |
| Revenue | 9 months, 2011-12-31 to 2012-09-28 | $487.0m | us-gaap:SalesRevenueNet |
| Cost of revenue | 3 months, 2012-06-30 to 2012-09-28 | $110.4m | us-gaap:CostOfGoodsAndServicesSold |
| Cost of revenue | 9 months, 2011-12-31 to 2012-09-28 | $337.2m | us-gaap:CostOfGoodsAndServicesSold |
| Gross profit | 3 months, 2012-06-30 to 2012-09-28 | $51.0m | us-gaap:GrossProfit |
| Gross profit | 9 months, 2011-12-31 to 2012-09-28 | $149.8m | us-gaap:GrossProfit |
| Selling, general and administrative | 3 months, 2012-06-30 to 2012-09-28 | $20.3m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Selling, general and administrative | 9 months, 2011-12-31 to 2012-09-28 | $60.1m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Operating income | 3 months, 2012-06-30 to 2012-09-28 | $2.1m | us-gaap:OperatingIncomeLoss |
| Operating income | 9 months, 2011-12-31 to 2012-09-28 | $24.4m | us-gaap:OperatingIncomeLoss |
| Interest expense | 3 months, 2012-06-30 to 2012-09-28 | $4.4m | us-gaap:InterestExpense |
| Interest expense | 9 months, 2011-12-31 to 2012-09-28 | $13.2m | us-gaap:InterestExpense |
| Income tax | 3 months, 2012-06-30 to 2012-09-28 | $5.4m | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 9 months, 2011-12-31 to 2012-09-28 | $10.1m | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months, 2012-06-30 to 2012-09-28 | −$7.6m | us-gaap:NetIncomeLoss |
| Net income | 9 months, 2011-12-31 to 2012-09-28 | $757.0k | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months, 2012-06-30 to 2012-09-28 | −$0.32 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 9 months, 2011-12-31 to 2012-09-28 | $0.03 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months, 2012-06-30 to 2012-09-28 | −$0.32 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 9 months, 2011-12-31 to 2012-09-28 | $0.03 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months, 2012-06-30 to 2012-09-28 | 23,646,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 9 months, 2011-12-31 to 2012-09-28 | 23,924,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 9 months, 2011-12-31 to 2012-09-28 | $39.5m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 9 months, 2011-12-31 to 2012-09-28 | $33.6m | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Cash and equivalents | at 2012-09-28 | $10.8m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | at 2012-09-28 | $261.7m | us-gaap:AssetsCurrent |
| Total assets | at 2012-09-28 | $891.9m | us-gaap:Assets |
| Current liabilities | at 2012-09-28 | $92.3m | us-gaap:LiabilitiesCurrent |
| Total liabilities | at 2012-09-28 | $411.3m | us-gaap:Liabilities |
| Long-term debt | at 2012-09-28 | $230.2m | us-gaap:LongTermDebtNoncurrent |
| Shareholders' equity | at 2012-09-28 | $480.7m | us-gaap:StockholdersEquity |

## Management's discussion and analysis

As filed, 65,325 characters.

### Our Business

We operate our business in two reportable segments – Implantable Medical and Electrochem Solutions (“Electrochem”). The Company’s customers include large multi-national original equipment manufacturers (“OEMs”). The Implantable Medical segment (formerly Greatbatch Medical) is comprised of our Greatbatch Medical and QiG Group brands and designs and manufactures medical devices and components for the cardiac rhythm management (“CRM”), neuromodulation, vascular access and orthopaedic markets. Additionally, Implantable Medical offers value-added assembly and design engineering services. As a result of the strategy put in place over three years ago, Implantable Medical now offers its customers complete medical devices including design, development, manufacturing, regulatory submission and supporting worldwide distribution. This medical device strategy is being facilitated through the QiG Group (“QiG”) and leverages the component technology of Greatbatch in our core markets: cardiovascular, neuromodulation and orthopaedic. Once QiG designs and develops a medical device, it is manufactured by Greatbatch Medical. The operating expenses of QiG are included within the Implantable Medical segment.

Electrochem provides industry-leading total power solutions for rechargeable and non-rechargeable battery power systems, charging and docking stations, and power supplies, for critical applications largely in the portable medical and energy markets, where safety, reliability, quality and innovation are critical. Electrochem’s product lines cover a number of highly-customized battery-powered applications in remote and demanding environments, including down hole drilling tools and in life-saving and life-enhancing applications, including automated external defibrillators, portable oxygen concentrators, ventilators and powered surgical tools, among others. Electrochem’s portable medical product line sales were significantly enhanced through the Micro Power Electronics, Inc. (“Micro Power”) acquisition in December 2011.

### Our Acquisitions

On December 15, 2011, we acquired all of the outstanding stock of Micro Power headquartered in Beaverton, OR. Micro Power is a leading supplier of custom battery solutions, serving the portable medical, military and handheld automatic identification and data collection markets. Micro Power’s commercial portfolio is highly complementary to the products and services offered by Electrochem. The results of Micro Power were included in our Electrochem segment from the date of acquisition. The aggregate purchase price of Micro Power was $71.8 million, which we funded with cash on hand and $45 million borrowed under our revolving credit facility. Total assets acquired from Micro Power were $88.2 million. Total liabilities assumed from Micro Power were $16.4 million. For the first nine months of 2012, Micro Power added approximately $62.8 million to our revenue.

On February 16, 2012, we purchased all of the outstanding common stock of NeuroNexus Technologies, Inc. (“NeuroNexus”) headquartered in Ann Arbor, MI. NeuroNexus is an active implantable medical device design firm specializing in developing and commercializing neural interface technology, components and systems for neuroscience and clinical markets. NeuroNexus has an extensive intellectual property portfolio, core technologies and capabilities to support the development and manufacturing of innovative neural interface devices across a wide range of functions including neuromodulation, sensing, optical stimulation and targeted drug delivery applications. The results of NeuroNexus were included in our Implantable Medical segment from the date of acquisition. The aggregate purchase price of NeuroNexus was $13.2 million, which we funded with cash on hand and $10 million borrowed under our revolving credit facility. Total assets acquired from NeuroNexus were $14.6 million. Total liabilities assumed from NeuroNexus were $1.4 million. For the first nine months of 2012, NeuroNexus added approximately $1.7 million to our revenue.

\- 34 -

### Our Customers

Implantable Medical customers include leading OEMs, in alphabetical order here and throughout this report, such as Biotronik, Boston Scientific, Johnson & Johnson, Medtronic, Smith & Nephew, Sorin Group, St. Jude Medical, Stryker and Zimmer. The nature and extent of our selling relationships with each OEM varies in terms of breadth of products purchased, purchased product volumes, length of contractual commitment, ordering patterns, inventory management and selling prices. During the nine months ended September 28, 2012, Boston Scientific, Johnson & Johnson, Medtronic and St. Jude Medical collectively accounted for 50% of our total Company sales.

Electrochem’s customers are primarily companies involved in demanding markets with sophisticated total power solutions needs, such as in the portable medical and energy markets. Some of our larger OEM customers include Phillips Healthcare, Physio-Control, Covidien, Ethicon Endo-Surgery, Carefusion, Halliburton and Weatherford International.

### Financial Overview

Third quarter 2012 sales increased 22% over the prior year period to $161.3 million. This increase was driven by our acquisitions, which added $21.6 million to sales, as well as growth of 13% in CRM/neuromodulation and 20% in vascular access revenue. Third quarter results also included the impact of foreign currency exchange rate fluctuations, which lowered orthopaedic sales by approximately $2 million in comparison to the prior year. On an organic constant currency basis, sales for the third quarter increased 8% versus the prior year as the benefits described above were partially offset by fewer customer product launches and development opportunities due to operational issues within our orthopaedic operations, which are aggressively being addressed through our consolidation initiatives. For the nine months ended September 28, 2012, sales increased 14% primarily due to our acquisitions, which added approximately $64.5 million to revenue, partially offset by foreign currency exchange rate fluctuations which lowered orthopaedic sales by approximately $6 million.

We prepare our consolidated financial statements in accordance with generally accepted accounting principles in the United States of America (“GAAP”). Additionally, we consistently report and discuss in our quarterly earnings releases and investor presentations adjusted operating income and margin, adjusted net income and adjusted earnings per diluted share. These adjusted amounts consist of GAAP amounts excluding the following adjustments to the extent they occur during the period: (i) facility consolidation, manufacturing transfer and system integration charges, (ii) asset write-down and disposition charges, (iii) severance charges in connection with corporate realignments or a reduction in force (iv) the impact of non-cash charges to interest expense due to the accounting change governing convertible debt, (v) unusual or infrequently occurring items, (vi) certain research and development expenditures (such as medical device design verification testing (“DVT”) expenses in connection with our development of a neuromodulation platform), (vii) gain/loss on the sale of investments and (viii) the income tax (benefit) related to these adjustments. We believe that reporting these amounts provides important supplemental information to our investors and creditors seeking to understand the financial and business trends relating to our financial condition and results of operations. Additionally, certain performance-based compensation incentives provided to our executives are determined utilizing these adjusted amounts.

\- 35 -

A reconciliation of GAAP operating income to adjusted amounts is as follows (in thousands):

|  | Three Months Ended September 28, 2012 | September 30, 2011 | Nine Months Ended September 28, 2012 | September 30, 2011 |
| --- | ---: | ---: | ---: | ---: |
| Operating income as reported | $2,127 | $12,888 | $24,416 | $49,157 |
| Adjustments: |  |  |  |  |
| Inventory step-up amortization (COS) | — | — | 532 | — |
| Medical device DVT expenses (RD&E) | 1,224 | 1,639 | 3,839 | 2,863 |
| Consolidation and optimization costs | 14,778 | 164 | 20,801 | 425 |
| Integration expenses | 232 | — | 1,287 | — |
| Asset dispositions, severance and other | 303 | 23 | 1,893 | (591) |
| Adjusted operating income | $18,664 | $14,714 | $52,768 | $51,854 |
| Adjusted operating margin | 11.6% | 11.2% | 10.8% | 12.1% |

GAAP operating income for the quarter and year-to-date periods of 2012 was $2.1 million and $24.4 million, respectively, compared to $12.9 million and $49.2 million, respectively, for the comparable 2011 periods. These decreases were primarily due to the charges recorded in connection with the consolidation of our Swiss orthopaedic operations, as well as other productivity initiatives (See Cost Savings and Consolidation Efforts section). As a result of the progress we have made on these initiatives, we now expect that our adjustments to non-GAAP operating income for 2012 will be $40 million to $45 million compared to the $20 million to $30 million estimate provided last quarter. It is important to note that, while we are increasing the 2012 estimate for these expenses, the overall estimate to complete our consolidation initiatives remains unchanged and the impact to our operating cash flows will be significantly less than the charges incurred.

Adjusted operating income was $18.7 million in the third quarter of 2012, compared to $14.7 million for the comparable 2011 period. This 27% increase was primarily a result of our increased revenue as well as the initiatives we began to implement in the second quarter to leverage our operating infrastructure, and optimize our net research, development and engineering (“RD&E”) investments. This included the reallocation of RD&E resources to higher priority projects, the postponement of some RD&E projects, as well as the decision to pursue various alternatives to monetize some of our existing intellectual property that are outside our core business. As a result of these decisions, we expect RD&E for the second half of 2012 to be slightly lower than the first half. In comparison to the second quarter of 2012, net RD&E declined $0.9 million. For the first nine months of 2012, adjusted operating income was $52.8 million compared to $51.9 million for the 2011 period as the benefits described above were offset by the operational issues at our Swiss orthopaedic facilities.

Based upon our results for the first nine months of 2012, we still expect that revenue will be in line with our original guidance as the weakness we are seeing in our orthopaedics revenue is being offset by stronger than expected performance from our CRM and portable medical product lines. Consistent with last quarter, we expect that our full year 2012 adjusted operating income as a percentage of sales and adjusted diluted EPS will be at the lower end of our guidance provided at the beginning of the year due to lower than expected profitability from our Swiss operations. Overall, we estimate that the operational issues at our Swiss orthopaedic facilities decreased our adjusted diluted EPS for the first nine months of 2012 by approximately $0.13 per share versus the first nine months of 2011.

\- 36 -

GAAP and adjusted diluted EPS for the third quarter of 2012 were a loss of $0.32 and income of $0.46 per share, respectively, compared to $0.30 and $0.41 per share, respectively, for the third quarter of 2011. For the first nine months of 2012, GAAP and adjusted diluted EPS were $0.03 and $1.25 per share, respectively, compared to $1.16 and $1.29 per share, respectively, for the same period of 2011.

A reconciliation of GAAP net income (loss) and diluted EPS to adjusted amounts is as follows (in thousands, except per share amounts):

|  | Three Months Ended September 28, 2012 Net Income (Loss) | Impact Per Diluted Share | September 30, 2011 Net Income (Loss) | Impact Per Diluted Share | Nine Months Ended September 28, 2012 Net Income (Loss) | Impact Per Diluted Share | September 30, 2011 Net Income (Loss) | Impact Per Diluted Share |
| --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Net income (loss) as reported | $(7,561) | $(0.32) | $6,989 | $0.30 | $757 | $0.03 | $27,483 | $1.16 |
| Adjustments: |  |  |  |  |  |  |  |  |
| Inventory step-up amortization (COS) | — | — | — | — | 346 | 0.01 | — | — |
| Medical device DVT expenses (RD&E) | 796 | 0.03 | 1,065 | 0.05 | 2,495 | 0.10 | 1,861 | 0.08 |
| Consolidation and optimization costs(a) | 11,119 | 0.46 | 107 | — | 15,034 | 0.63 | 276 | 0.01 |
| Integration expenses | 151 | 0.01 | — | — | 837 | 0.03 | — | — |
| Asset dispositions, severance and other | 197 | 0.01 | 15 | — | 1,230 | 0.05 | (384) | (0.02) |
| Gain on cost method investments, net(b) | (228) | (0.01) | — | — | (228) | (0.01) | (2,751) | (0.12) |
| CSN conversion option discount amortization(c) | 1,498 | 0.06 | 1,391 | 0.06 | 4,413 | 0.18 | 4,097 | 0.17 |
| Swiss tax impact(d) | 5,008 | 0.21 | — | — | 5,008 | 0.21 | — | — |
| Adjusted net income and diluted EPS(e) | $10,980 | $0.46 | $9,567 | $0.41 | $29,892 | $1.25 | $30,582 | $1.29 |
| Adjusted diluted weighted average shares(f) | 24,011 |  | 23,611 |  | 23,924 |  | 23,663 |  |

(a) Net of tax amounts computed using U.S. and foreign statutory tax rates of 35% and 22.5%, respectively, for items incurred in those geographic locations.

(b) Pre-tax amount is $350 thousand for both the quarter and year-to-date periods for 2012 and $4.2 million for the year-to-date period of 2011.

(c) Pre-tax amount is $2.3 million and $6.8 million for the 2012 quarter and year-to-date periods, respectively, and $2.1 million and $6.3 million for the 2011 quarter and year-to-date periods, respectively.

(d) Relates to the loss of our Swiss tax holiday due to our decision to discontinue manufacturing in Switzerland, as well as the establishment of a valuation allowance on our Swiss deferred tax assets as it is more likely than not that they will not be fully realized.

(e) The per share data in this table has been rounded to the nearest $0.01 and therefore may not sum to the total.

(f) Weighted average diluted shares for the third quarter of 2012 includes 365 thousand shares of dilution related to outstanding stock incentive awards that were not dilutive for GAAP EPS purposes.

\- 37 -

### Our CEO’s View

We continue to drive growth in our core business and benefited from favorable market trends and new product introductions within our portable medical product line. During the quarter, we continued to deepen our relationship with our larger OEM customers and successfully negotiated several long-term agreements which secured existing revenue streams, as well as expanded those relationships into other product lines. As we move forward, our goal is to continue to drive core growth through an increased focus on and investment in sales and marketing and the commercialization of our medical device pipeline. Additionally, we are focused on further improving profitability by leveraging our infrastructure and optimizing our research and development investment.

Key points about the third quarter of 2012 are as follows:

- We have a high-growth portable medical product line.
- We have added sales and marketing resources to our Implantable Medical segment focused on growing our revenues faster than the market.
- We are aggressively addressing our Swiss orthopaedic issues with a consolidation plan that is on track to deliver improved operating results starting in early 2013.
- We have reviewed and prioritized our RD&E investment with a goal of improving our return on invested capital both near-term and long term.
- We will continue our on-going productivity efforts with suppliers, lean manufacturing processes and focused cost reductions.
- We are aware of the large difference between our GAAP EPS and Adjusted EPS because of the expenses incurred for our productivity and consolidation initiatives. We expect the difference between GAAP and Adjusted EPS to be much smaller next year and to realize the productivity from our investments we are making this year.
- We are confirming our adjusted diluted EPS guidance at the low end of the range and are cautiously optimistic for the fourth quarter given the continued challenges surrounding key CRM players.
- Our cash flow from operations remains strong and continues to provide the funding needed to execute on all of our strategic objectives.

I am pleased with the progress we have made on our strategic objectives and remain confident that these initiatives will improve the long-term growth and profitability of our Company.

### Product Development

*Implantable Medical* - As part of the natural evolution of our Company, in 2008, we reassigned 40 Greatbatch Medical engineers to create the QiG Group in order to help facilitate the development of complete medical devices for our customers. In creating QiG, we pooled and focused the tremendous talent, resources and capacity for innovation within our organization. Today, QiG encompasses approximately 120 research and development professionals working in facilities in six states and focused on three compelling therapeutic areas: cardiovascular, neuromodulation and, longer-term, orthopaedics. Additionally, QiG has established partnerships with nearly a dozen key physicians who are highly specialized in these areas. These partnerships are helping us to design medical devices from the ground up with features that will meet the needs of today’s practicing clinicians.

As a result of the investments we have made, we are now able to provide our customers with complete medical devices. This includes development and regulatory submissions, as well as manufacturing and supporting worldwide distribution. These medical devices are full product solutions that complement our OEM customers’ products and utilize the component expertise and capabilities residing within Greatbatch. The benefits to our OEM customers include shortening the time to market for these devices by accelerating the velocity of innovation, optimizing their supply chain and ultimately providing them with cost efficiencies.

\- 38 -

Within QiG, we are utilizing a disciplined and diversified portfolio approach with three investment modes: strategic equity investments; OEM initiated medical device projects; and independent market driven medical device developments each to be sold by an OEM or distribution partner. The QiG Group employs a disciplined and thorough process for evaluating these opportunities. A scorecard process is utilized to review and select the most strategically valuable ideas to pursue, taking into account a host of variables, including the market opportunity, regulatory pathway and reimbursement, market need and market potential, intellectual property and projected financial return.

Today we have six strategic equity investments and have developed or are in the process of developing nearly a dozen medical devices in conjunction with our OEM partners, which are beginning to provide a return on the investment we have made. Additionally, we have four new medical devices that we are independently working on that are in various stages of development. While we do not intend to discuss each of these projects individually each quarter, we will discuss significant milestones as they occur. Some of the medical device projects that we currently are working on include:

Cardiovascular portfolio - Venous and arterial introducers, anti-microbial coatings, steerable delivery systems, and MRI conditional brady, gastric stimulation and sleep apnea leads. During 2012, we received U.S. Food and Drug Administration (“FDA”) 510(k) clearance on our transradial catheter sheath introducer and steerable delivery sheath for atrial fibrillation ablation and received the CE mark for distribution of our transseptal needle that supports access and delivery of ablation therapies for atrial fibrillation.

Neuromodulation portfolio – With regards to Algostim, our spinal cord stimulator for the treatment of chronic pain in the trunk and limbs, during the second quarter of 2012, we provided an update on the timing of our premarket approval application (“PMA”) submission given the extension of our DVT testing timeline. We continue to make strong technical progress on the development of this device and continue to retire critical milestones needed for program completion and the ultimate submission to regulatory authorities, which we still expect in the second half of 2013.

Additionally, we continue to receive strong interest from numerous world-class medical device companies, who appreciate the unique opportunity to market and distribute Algostim to interventional pain physicians, neurosurgeons and orthopaedic spine surgeons around the world. We believe Algostim’s unique features and benefits will allow the right commercial partner to capture significant market share in today’s $1.3 billion spinal cord stimulation market, which continues to see double digit market growth. We look forward to sharing more details regarding Algostim and our commercial partner progress as well as our other three devices that we are independently developing at our next investor day conference which will be scheduled early next year.

Approximately $0.5 million of the NeuroNexus purchase price in February 2012 was allocated to the estimated fair value of acquired IPR&D projects that expect to generate cash flows but have not yet reached technological feasibility, and thus were classified as an indefinite-lived intangible asset until the completion or abandonment of the associated projects. The value assigned to IPR&D related to the development of micro-electrodes for deep brain mapping and electrocorticography, and is expected to be commercialized by 2014. There have been no significant changes from our original estimates with regards to these projects.

\- 39 -

*Electrochem* - Electrochem continues to win new customers, new applications and next generation products. Our core competencies enable us to be well-positioned to win existing share and additional new product introductions based on our experience in packaging solutions, our customer relationships, our investment in technology and facilities, our capacity to service our customers, and our legacy of delivering highly reliable and innovative solutions to the medical marketplace.

The 2012 growth in Electrochem is being driven by successful product launches into the higher growth, higher value portable medical market. Gaining better access to this attractive market was one of the main drivers behind our acquisition of Micro Power as it provides us with a significant opportunity for growth given its $400 million market size.

Additionally, this market is benefiting from favorable market trends as patient care shifts from clinical settings to the home and as an aging population drives the need for lightweight and portable devices for patients and caregivers. These favorable trends are expected to allow this market to grow faster than our legacy markets over the next several years. Finally, this market is also attractive to us given that it has long product life cycles that should provide stability and diversification to our revenue base.

### Cost Savings and Consolidation Efforts

In 2012 and 2011, we recorded charges in Other Operating (Income) Expense, Net in the Condensed Consolidated Statements of Operations related to cost savings and consolidation efforts. These initiatives were undertaken to improve our operational efficiencies and profitability. Additional information regarding the timing, cash flow and amount of future expenditures is set forth in Note 9 “Other Operating (Income) Expense, Net” of the Notes to the Condensed Consolidated Financial Statements contained in Item 1 of this report, as well as the “Liquidity and Capital Resources” section of this Item.

Over the last two years, we have been implementing a multi-faceted plan to further enhance, optimize and leverage our orthopaedics operations. This plan includes the construction of an orthopaedic manufacturing facility in Fort Wayne, IN, updating our Indianapolis, IN facility to streamline operations, increase capacity, and further expand capabilities, and in the third quarter of 2012, we finalized and initiated plans to transfer most major functions currently performed at our facilities in Orvin and Corgemont, Switzerland into our Fort Wayne, IN and Tijuana, Mexico facilities. The total capital investment expected for these initiatives is between $25 million and $35 million, of which $21 million has been expended to date. Total expense expected to be incurred for these initiatives is between $30 million and $36 million, of which $15.4 million has been incurred to date.

Near the end of 2011, we initiated plans to optimize and expand our manufacturing infrastructure in order to support our medical device strategy. This will include the transfer of certain product lines to lower cost facilities, expansion of two of our existing facilities, as well as the purchase of equipment to create additional capacity for the manufacture of medical devices and create additional cost savings. Total capital investment under these initiatives is expected to be between $15 million to $20 million of which approximately $8.5 million has been expended to date. Total expenses expected to be incurred on these projects is between $2.5 million to $3.5 million of which $1.3 million has been incurred to date.

These orthopaedic and medical device initiatives are expected to be completed over the next two to three years and are expected to generate approximately $10 million to $15 million of annual cost savings and increase our capacity in order to support our growth and the manufacturing of complete medical devices.

\- 40 -

In 2011, we initiated plans to upgrade our existing global ERP system. This initiative is expected to be completed over the next two years. Total capital investment under this initiative is expected to be approximately $4 million to $5 million of which approximately $2.8 million has been expended to date. Total expenses expected to be incurred on this initiative is between $5 million to $7 million of which $4.7 million has been incurred to date.

### Government Regulation

The Patient Protection and Affordable Care Act and the Health Care and Education Affordability Reconciliation Act (collectively “Health Care Reform”) legislated broad-based changes to the U.S. health care system that could significantly impact our business operations and financial results, including higher or lower revenue, as well as higher employee medical costs and taxes. Health Care Reform imposes significant new taxes on medical device OEMs, which will result in a significant increase in the tax burden on our industry and which could have a material negative impact on our financial condition, results of operations and our cash flows. Other elements of Health Care Reform such as comparative effectiveness research, an independent payment advisory board, payment system reforms including shared savings pilots and other provisions could meaningfully change the way healthcare is developed and delivered, and may materially impact numerous aspects of our business, results of operations and financial condition. Many significant parts of Health Care Reform will be phased in over the next several years and require further guidance and clarification in the form of regulations. Management is currently evaluating the impact that the new medical device tax will have on our results from operations beginning in 2013, and has preliminarily estimated that it will reduce operating income by up to $2 million. This amount assumes that this tax applies to the first medical device sale in the U.S. and is based upon a wholesale price.

On August 22, 2012, the U.S. Securities and Exchange Commission (“SEC”) issued a rule under Section 1502 of the Dodd-Frank Wall Street Reform and Consumer Protection Act requiring companies to publicly disclose their use of conflict minerals that originated in the Democratic Republic of the Congo (DRC) or an adjoining country. Under the adopted rule, issuers are required to conduct a “reasonable” due-diligence process to ascertain the source of conflict minerals, defined as tantalum, tin, gold or tungsten, that are necessary to the functionality or production of their manufactured or contracted to be manufactured products. Companies are required to provide this disclosure on a new form to be filed with the SEC called Form SD. Companies are required to file Form SD on May 31, 2014 for the 2013 calendar period and annually on May 31 every year thereafter. We anticipate additional, new compliance costs to be incurred since our business utilizes all of the minerals specified in the rule.

\- 41 -

### Our Financial Results

We utilize a fifty-two, fifty-three week fiscal year ending on the Friday nearest December 31st. For 52-week years, each quarter contains 13 weeks. The third quarter and year-to-date periods of 2012 and 2011 ended on September 28, and September 30, respectively, and each contained 13 weeks and 39 weeks, respectively. The commentary that follows should be read in conjunction with our Condensed Consolidated Financial Statements and related notes and with the Management’s Discussion and Analysis of Financial Condition and Results of Operations contained in our Annual Report on Form 10-K for the fiscal year ended December 30, 2011.

The following table presents certain selected financial information derived from our Condensed Consolidated Financial Statements for the periods presented (dollars in thousands, except per share data):

| Sales: Implantable Medical | Three Months Ended September 28, 2012 | September 30, 2011 | Change $% |  | Nine Months Ended September 28, 2012 | September 30, 2011 | Change $% |  |
| --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| CRM/Neuromodulation | $80,246 | $70,731 | $9,515 | 13% | $235,406 | $226,492 | $8,914 | 4% |
| Vascular Access | 13,674 | 11,396 | 2,278 | 20% | 37,791 | 32,639 | 5,152 | 16% |
| Orthopaedic | 27,173 | 31,131 | (3,958) | -13% | 91,079 | 108,642 | (17,563) | -16% |
| Total Implantable Medical | 121,093 | 113,258 | 7,835 | 7% | 364,276 | 367,773 | (3,497) | -1% |
| Electrochem |  |  |  |  |  |  |  |  |
| Portable Medical | 20,219 | 1,954 | 18,265 | NA | 59,346 | 6,105 | 53,241 | NA |
| Energy/Environmental | 16,192 | 13,955 | 2,237 | 16% | 51,441 | 45,813 | 5,628 | 12% |
| Other | 3,836 | 2,551 | 1,285 | 50% | 11,928 | 7,385 | 4,543 | 62% |
| Total Electrochem | 40,247 | 18,460 | 21,787 | 118% | 122,715 | 59,303 | 63,412 | 107% |
| Total sales | 161,340 | 131,718 | 29,622 | 22% | 486,991 | 427,076 | 59,915 | 14% |
| Cost of sales | 110,386 | 89,811 | 20,575 | 23% | 337,216 | 291,395 | 45,821 | 16% |
| Gross profit | 50,954 | 41,907 | 9,047 | 22% | 149,775 | 135,681 | 14,094 | 10% |
| Gross profit as a % of sales | 31.6% | 31.8% |  |  | 30.8% | 31.8% |  |  |
| Selling, general and administrative expenses (SG&A) | 20,274 | 17,760 | 2,514 | 14% | 60,053 | 53,980 | 6,073 | 11% |
| SG&A as a % of sales | 12.6% | 13.5% |  |  | 12.3% | 12.6% |  |  |
| Research, development and engineering costs, net (RD&E) | 13,240 | 11,072 | 2,168 | 20% | 41,325 | 32,710 | 8,615 | 26% |
| RD&E as a % of sales | 8.2% | 8.4% |  |  | 8.5% | 7.7% |  |  |
| Other operating (income) expense, net | 15,313 | 187 | 15,126 | NA | 23,981 | (166) | 24,147 | NA |
| Operating income | 2,127 | 12,888 | (10,761) | NA | 24,416 | 49,157 | (24,741) | -50% |
| Operating margin | 1.3% | 9.8% |  |  | 5.0% | 11.5% |  |  |
| Interest expense | 4,401 | 4,125 | 276 | 7% | 13,176 | 12,802 | 374 | 3% |
| Interest income | — | (1) | 1 | NA | (1) | (9) | 8 | -89% |
| Gain on cost method investments, net | (350) | — | (350) | NA | (350) | (4,232) | 3,882 | -92% |
| Other (income) expense, net | 248 | (475) | 723 | -152% | 774 | 766 | 8 | 1% |
| Provision for income taxes | 5,389 | 2,250 | 3,139 | 140% | 10,060 | 12,347 | (2,287) | -19% |
| Effective tax rate | NA | 24.4% |  |  | 93.0% | 31.0% |  |  |
| Net income (loss) | $(7,561) | $6,989 | $(14,550) | NA | $757 | $27,483 | $(26,726) | -97% |
| Net margin | -4.7% | 5.3% |  |  | 0.2% | 6.4% |  |  |
| Diluted earnings (loss) per share | $(0.32) | $0.30 | $(0.62) | NA | $0.03 | $1.16 | $(1.13) | -97% |

\- 42 -

### Sales

Third quarter 2012 sales increased 22% over the prior year period to $161.3 million. This increase was driven by our recent acquisitions, which added $21.6 million to sales, as well as a 20% increase in vascular access revenue and 13% growth in our CRM product line. Third quarter results also included the impact of foreign currency exchange rate fluctuations, which lowered orthopaedic sales by approximately $2 million in comparison to the prior year. On an organic constant currency basis, sales for the third quarter increased 8% versus the prior year as the benefits described above were partially offset by continued weakness within our orthopaedics product line. For the year-to-date period, sales increased 14% primarily due to the same reasons that impacted the third quarter results. For the first nine months of 2012, our acquisitions added approximately $64.5 million to revenue while foreign currency exchange rate fluctuations lowered orthopaedic sales by approximately $6 million. At this time, we still expect to achieve our 13% to 17% growth guidance for total sales set at the beginning of the year given stronger than expected performance from our CRM and portable medical product lines.

***Implantable Medical –*** CRM and neuromodulation sales for the third quarter of 2012 increased 13% compared to the prior year to $80.2 million due to more level customer inventory ordering patterns in 2012 in comparison to 2011, as well as easier comparables versus the 2011 period. For the year-to-date period, CRM and neuromodulation sales were 4% above the prior year, which is ahead of our expectations and above market growth rates.

This rate of growth is not expected to continue in the fourth quarter of 2012 as the fourth quarter of 2011 is a much tougher comparable. Additionally, given the continued ongoing challenges surrounding key CRM customers it is important to note that our visibility to customer ordering patterns is over a short period of time and that any significant customer field actions or relative market share shifts among OEM manufacturers could impact our results. We believe that the impact of these factors is somewhat muted by the fact that we have business with all of the key CRM OEMs and have significantly diversified our revenue base over the last four years. We remain cautiously optimistic regarding our CRM business over the short term, but are confident that over the long-term our increased focus on sales and marketing, as well as the increased pace of new product development opportunities we are winning, will allow us to grow this product line faster than the underlying market.

Third quarter and year-to-date 2012 sales for the vascular access product line increased 20% and 16%, respectively, in comparison to the prior year periods and were primarily driven by the commercialization of new medical devices, as well as market growth. We continue to see a high level of interest in our medical device programs from our OEM customers. However, we now believe that our medical device revenue for 2012 will be $8 million to $10 million, down from the $10 million to $15 million guidance we provided earlier in the year. This decrease is primarily due to a lower rate of acceptance for our medical devices than originally anticipated. If achieved, our 2012 projected medical device revenue will still represent a significant increase over our 2011 medical device sales of $5 million.

As discussed more fully in Item 1A “Risk Factors” contained in our Form 10-K, our business depends on a continuous supply of raw materials from a limited number of suppliers. If an unforeseen interruption of supply were to occur, we may be unable to obtain substitute sources for these raw materials on a timely basis or on terms acceptable to us, which could harm our ability to manufacture our products profitably or on time. Additionally, we may be unable to quickly establish additional or replacement suppliers for these materials as there are a limited number of worldwide suppliers. During the first quarter of 2012, one of the companies in our extended supply chain for cyclododecatriene (“CDT”), which we use to manufacture catheters, experienced a fire at one of its facilities and production is expected to be down until the fourth quarter of 2012. For this raw material, we maintain minimum safety stock levels and are actively working with vendors to secure supply. Accordingly, we do not anticipate that this interruption in supply will materially impact our results of operations.

\- 43 -

Orthopaedic product line sales for the third quarter and year-to-date periods of 2012 declined 13% (-6% constant currency) and 16% (-11% constant currency), respectively, compared to the same periods of 2011. Foreign currency exchange rate fluctuations decreased orthopaedic revenue by approximately $2 million in the third quarter of 2012 ($6 million year-to-date) in comparison to the prior year. The remaining decline in third quarter and year-to-date 2012 orthopaedic sales was a result of price concessions provided to customers, as well as fewer customer product launches and development opportunities due to operational issues within our orthopaedic facilities, which are aggressively being addressed. Given the softness that we are seeing in our orthopaedic product line, we do not expect to achieve the revenue growth assumptions previously provided for that product line.

In addition to the consolidation of manufacturing, we are also streamlining our Swiss orthopaedic product line. This will include ceasing production on several non-core products. We are evaluating several alternatives and options for these product lines in order to help ensure a smooth transition for our customers, which could include selling these discontinued product lines to an independent third party. Our current estimate is that the discontinuance of these products will reduce our 2013 Orthopaedic revenue by approximately $10 to $15 million.

***Electrochem –*** Third quarter and year-to-date 2012 sales for Electrochem increased $21.8 million and $63.4 million, respectively versus the comparable 2011 periods. 2012 third quarter Electrochem sales included $20.9 million ($62.8 million year-to-date) of revenue related to the acquisition of Micro Power in December 2011. On an organic basis, Electrochem revenue increased 5% and 1% for the quarter and year-to-date periods, respectively, in comparison to the prior year due to continued strength in the energy markets. The Micro Power acquisition continues to exceed our initial expectations, and is being driven by successful product launches into the higher growth, higher value portable medical market. This market is benefiting from the shifting of patient care from clinical settings to the home and an aging population, which is driving the need for lightweight/portable devices for patients and caregivers. Our funnel of portable medical products from this acquisition continues to be full and is expected to drive high single digit revenue growth for this product line for the next several years.

### Gross Profit

Changes to gross profit as a percentage of sales from the prior year were due to the following:

|  | Change From Prior Year Three Months | Nine Months |
| --- | ---: | ---: |
| Impact of acquisitions(a) | -2.2% | -1.6% |
| Excess capacity & Swiss production inefficiencies(b) | -0.7% | -1.7% |
| Volume and productivity(c) | 2.7% | 3.0% |
| Selling price(d) | -0.6% | -0.9% |
| Other | 0.6% | 0.2% |
| Total percentage point change to gross profit as a percentage of sales | -0.2% | -1.0% |

(a) Our gross profit percentage was impacted by the acquisition of Micro Power in December 2011, which had a lower gross margin percentage due to its higher percentage of material costs in comparison to our legacy businesses. Additionally, during the first quarter of 2012 we recognized $0.5 million of inventory step-up amortization in connection with this acquisition which will not reoccur in subsequent periods.

\- 44 -

(b) Our gross profit percentage was negatively impacted during 2012 due to production inefficiencies at our Swiss orthopaedic facilities. Additionally, as a result of the addition of our Fort Wayne facility in the second quarter of 2012, we experienced excess capacity costs in comparison to 2011. In accordance with our inventory accounting policy, excess capacity costs are expensed in the period they occur. We have aggressively begun to right-size our orthopaedic cost structure and have announced plans to enhance, optimize and leverage this business, which is expected to help improve our gross margin percentage starting in the first quarter of 2013.

(c) Our gross profit percentage benefitted from higher sales volumes, primarily CRM and vascular access, as well as production efficiencies gained at our manufacturing facilities as a result of our various lean and supply chain initiatives.

(d) Our gross profit percentage has been negatively impacted in comparison to the prior year by price concessions made to our larger OEM customers, which were given in exchange for long-term contracts.

Over the long-term, we expect to see gross margin improvements as a result of the consolidation of our orthopaedic operations and from various other productivity improvement initiatives that are being implemented (See Cost Savings and Consolidation Efforts section). Additionally, we expect our gross profit margin to improve as more system and device level products are introduced, which typically earn a higher margin.

### SG&A Expenses

Changes to SG&A expenses from the prior year were due to the following (in thousands):

|  | Change From Prior Year Three Months | Nine Months |
| --- | ---: | ---: |
| Impact of acquisitions(a) | $2,411 | $7,852 |
| Performance-based compensation(b) | 286 | (725) |
| Medical device strategy communication(c) | (12) | (562) |
| Other | (171) | (492) |
| Net increase in SG&A | $2,514 | $6,073 |

(a) Amounts represent the incremental SG&A expenses related to the acquisition of Micro Power and NeuroNexus.

(b) Amounts represent the change in performance-based compensation versus the prior year and is recorded based upon the actual results achieved. Performance-based compensation began to increase during the third quarter of 2012 as our revenue and operating results began to improve.

(c) Amounts represent the costs incurred during 2011 in connection with the communication of our medical device strategy to shareholders, customers and associates including costs incurred for our Investor Day held in the first quarter of 2011.

\- 45 -

### RD&E Expenses, Net

Net RD&E costs are comprised of the following (in thousands):

|  | Three Months Ended September 28, 2012 | September 30, 2011 | Nine Months Ended September 28, 2012 | September 30, 2011 |
| --- | ---: | ---: | ---: | ---: |
| Research and development costs | $6,324 | $5,160 | $18,864 | $13,672 |
| Engineering costs | 9,787 | 8,330 | 28,956 | 25,897 |
| Less cost reimbursements | (2,871) | (2,418) | (6,495) | (6,859) |
| Engineering costs, net | 6,916 | 5,912 | 22,461 | 19,038 |
| Total RD&E, net | $13,240 | $11,072 | $41,325 | $32,710 |

Net RD&E for the 2012 third quarter and year-to-date periods increased $2.2 million and $8.6 million, respectively, versus the 2011 periods. Approximately $0.9 million and $2.4 million, respectively, of this increase was a result of the operations from our recent acquisitions. The remainder of this increase can be attributed to the investment in the development of complete medical devices which totaled $6.5 million for the 2012 third quarter ($20.9 million year-to-date) compared to $6.2 million ($16.6 million year-to-date) for 2011. These amounts include $1.2 million ($3.8 million year-to-date) and $1.6 million ($2.9 million year-to-date), respectively, of DVT costs in connection with our development of a neuromodulation platform. When combined with SG&A expenses, total costs incurred in connection with our medical device initiatives totaled $27.3 million for the first nine months of 2012 versus $20.1 million for the comparable 2011 period.

During the second quarter of 2012, we began to implement an initiative to optimize our RD&E investments. This included the reallocation of RD&E resources to higher priority projects, the postponement of some RD&E projects, as well as the decision to pursue various alternatives to monetize some of our existing intellectual property that are outside our core business. As a result of these decisions, we expect RD&E for the second half of 2012 to be slightly lower than the first half. In comparison to the second quarter of 2012, net RD&E for the third quarter of 2012 declined $0.9 million.

\- 46 -

### Other Operating (Income) Expense, Net

Other operating (income) expense, net is comprised of the following (in thousands):

|  | Three Months Ended September 28, 2012 | September 30, 2011 | Nine Months Ended September 28, 2012 | September 30, 2011 |
| --- | ---: | ---: | ---: | ---: |
| Orthopaedic facility optimization(a) | $12,452 | $164 | $14,774 | $425 |
| Medical device facility optimization(a) | 388 | — | 1,282 | — |
| ERP system upgrade(a) | 1,938 | — | 4,745 | — |
| Integration costs(b) | 232 | — | 1,287 | — |
| Asset dispositions, severance and other(c) | 303 | 23 | 1,893 | (591) |
| Total other operating (income) expense, net | $15,313 | $187 | $23,981 | $(166) |

(a) Refer to “Cost Savings and Consolidation Efforts” section of this Item and Note 9 “Other Operating (Income) Expense, Net” of the Notes to the Condensed Consolidated Financial Statements contained in Item 1 for disclosures related to the timing and level of remaining expenditures for these initiatives.

(b) During 2012, we incurred costs related to the integration of Micro Power and NeuroNexus. These expenses were primarily for retention bonuses, travel costs in connection with integration efforts, and severance, which will not be required or incurred after the integrations are completed.

(c) During 2012 and 2011, we recorded (gains) write-downs in connection with various asset disposals, net of insurance proceeds received, if any. Additionally, during the second quarter of 2012, we incurred $1.2 million of costs related to the relocation of our global headquarters to Frisco, Texas.

### Interest Expense and Interest Income

Interest expense for the third quarter and year-to-date periods of 2012 increased over the comparable periods of 2011, primarily due to the increased discount amortization related to our convertible notes, which is being amortized utilizing the effective interest method.

Interest income for the third quarter and year-to-date periods of 2012 were relatively consistent with the comparable 2011 periods.

### Gain on Cost Method Investments, Net

In January 2011, we sold our cost method investment in IntElect Medical, Inc. (“IntElect”) in conjunction with Boston Scientific’s acquisition of IntElect. We obtained our ownership interest in IntElect through our acquisition of BIOMEC, Inc. in 2007 and two subsequent additional investments. This transaction resulted in a pre-tax gain of $4.5 million in the first quarter of 2011 and an additional $0.4 million gain during the third quarter of 2012. During the second quarter of 2011, we recorded a $0.3 million write down of one of our cost method investments based upon a recent stock offering by that company. The total carrying value of our cost and equity method investments is reviewed quarterly for changes in circumstance or the occurrence of events that suggest the Company’s investment may not be recoverable. The fair value of cost or equity method investments is not adjusted if there are no identified events or changes in circumstances that may have a material effect on the fair value of our investments. If such events should occur they could materially impact our financial results. The aggregate recorded amount of cost and equity method investments at September 28, 2012 was $9.3 million.

\- 47 -

### Other (Income) Expense, Net

Other (income) expense, net primarily includes the impact of foreign currency exchange rate fluctuations on transactions denominated in foreign currencies. We generally do not expect foreign currency exchange rate fluctuations to have a material impact on our financial results.

### Provision for Income Taxes

The effective tax rate (including discrete items) for the nine months ended September 28, 2012 was 93.0% versus 31.0% for the comparable 2011 period. This fluctuation was primarily attributable to approximately $5.0 million of tax charges recorded in connection with our Swiss orthopaedic consolidation. These charges related to the loss of our Swiss tax holiday, due to our third quarter 2012 decision to discontinue manufacturing in Switzerland, as well as the establishment of a valuation allowance on a portion of our Swiss deferred tax assets as it is more likely than not that they will not be fully realized. Additionally, our 2012 effective tax rate reflects the impact of losses resulting from our Swiss restructuring, the benefit of which are recorded at the lower Swiss effective tax rate, thus increasing the overall effective tax rate of the Company. The effective tax rate also does not include the benefit of the U.S. R&D tax credit, which expired at the end of 2011. The provision for income taxes for the third quarter of 2012 represents the amount necessary to bring our year-to-date effective tax rate to 93.0% and is based upon our full year expected GAAP effective tax rate.

We currently expect our 2012 annual GAAP effective tax rate to be between 90% and 95%, depending on the timing of expenses incurred in connection with the ongoing restructuring of the manufacturing operations in Switzerland. On an adjusted basis, which will exclude the impact of these consolidation costs, we expect our effective tax rate to be more in line with the U.S. statutory rate of 35%. We expect there to be continued volatility of this effective tax rate due to several factors, including changes in the mix of pre-tax income and the jurisdictions to which it relates, changes in tax laws and foreign tax holidays, business reorganizations, settlements with taxing authorities and foreign currency fluctuations. It is important to note that the impact of the loss of the Swiss tax holiday, valuation allowance on our Swiss deferred tax assets as well as the impact of the loss of the R&D tax credit could all be reversed at some point in the future if we attain a new tax holiday, if our operations in Switzerland become profitable, or if the R&D tax credit is reinstated. We currently have various tax planning initiatives in place that are aimed at reducing our effective tax rate over the long-term and is another strategic objective we are focused on.

### Liquidity and Capital Resources

*(Dollars in thousands)*

|  | As of September 28, 2012 | December 30, 2011 |
| --- | ---: | ---: |
| Cash and cash equivalents | $ 10,843 | $36,508 |
| Working capital | $169,378 | $170,907 |
| Current ratio | 2.83 | 2.82 |

The decrease in cash and cash equivalents from the end of 2011 was primarily due to the cash used in connection with our acquisitions, the purchase of property, plant and equipment, and the net repayment of long-term debt during the year partially offset by cash flows from operations. Our working capital and current ratio remained consistent with the prior year.

\- 48 -

***Revolving Line of Credit –*** We have a senior credit facility (the “Credit Facility”) consisting of a $400 million revolving line of credit, which can be increased to $600 million upon our request and approval by a majority of the lenders. The Credit Facility also contains a $15 million letter of credit subfacility and a $15 million swingline subfacility. The Credit Facility has a maturity date of June 24, 2016; provided, however, if our convertible notes are not repaid in full, modified or refinanced before March 1, 2013, the maturity date of the Credit Facility is March 1, 2013.

The Credit Facility is supported by a consortium of fourteen banks with no bank controlling more than 19% of the facility. As of September 28, 2012, each bank supporting the Credit Facility has an S&P credit rating of at least BBB or better, which is considered investment grade.

The Credit Facility requires us to maintain a rolling four quarter ratio of adjusted EBITDA to interest expense of at least 3.0 to 1.0. For the twelve month period ended September 28, 2012, our ratio of adjusted EBITDA to interest expense, calculated in accordance with our credit agreement, was 17.5 to 1.0, well above the required limit. The Credit Facility also requires us to maintain a total leverage ratio of not greater than 4.0 to 1.0. As of September 28, 2012, our total leverage ratio, calculated in accordance with our credit agreement, was 2.36 to 1.0, well below the required limit.

The Credit Facility contains customary events of default. Upon the occurrence and during the continuance of an event of default, a majority of the lenders may declare the outstanding advances and all other obligations under the Credit Facility immediately due and payable. See Note 6 “Debt” of the Notes to Condensed Consolidated Financial Statements in this report for a more detailed description of the Credit Facility.

As of September 28, 2012, we had $359 million of borrowing capacity available under the Credit Facility. This amount may vary from period to period based upon our debt and EBITDA levels, which impacts the covenant calculations discussed above. We believe that our cash flow from operations and the Credit Facility provide adequate liquidity to meet our short- and long- term funding needs.

***Operating activities –*** Cash flows from operations for the first nine months of 2012 were $39.5 million, which was below the comparable 2011 period of $58.5 million. The decrease from the prior year was primarily due to our lower net income and the payment of a higher level of performance-based compensation in 2012 (based upon 2011 results) in comparison to what was paid in 2011 (based upon 2010 results). Additionally, accounts receivable has increased since prior year primarily due to higher sales volumes as well as a slight increase due to timing of customer remittances.

***Investing activities –*** Net cash used in investing activities for the first nine months of 2012 was $52.4 million. This included $17.2 million of cash used in connection with our purchase of NeuroNexus and Micro Power, $1.7 million of net investment purchases, as well as $33.6 million used for the purchase of property, plant and equipment in connection with the consolidation and optimization initiatives discussed in the “Cost Savings and Consolidation Efforts” section of this Item (primarily the construction of our Fort Wayne facility which was completed in the second quarter of 2012) and routine capital expenditures. Our current expectation is that capital spending for the remainder of 2012 will be in the range of $10 million to $15 million, of which approximately half is discretionary in nature. We anticipate that cash on hand, cash flow from operations and availability under our Credit Facility will be sufficient to fund these capital expenditures. As part of our growth strategy, we have and will continue to consider targeted and opportunistic acquisitions.

\- 49 -

***Financing activities –*** Net cash used in financing activities for the first nine months of 2012 was $13.0 million compared to $31.0 million for the prior year period. During the first nine months of 2012, we borrowed $10 million under our revolving credit facility to fund the acquisition of NeuroNexus and utilized cash flow from operations to repay $24 million under our Credit Facility. Going forward, we expect excess cash flow from operations to be used to fund our consolidation initiatives and to pay down outstanding debt.

We currently have outstanding $197.8 million of convertible subordinated notes, which are due to mature on June 15, 2013. We currently intend to utilize availability under the Credit Facility and cash flow from operations to repay the notes, which is specifically permitted under the terms of the Credit Facility, and is expected to occur in February 2013.

***Capital Structure –*** As of September 28, 2012, our capital structure consisted of $197.8 million of convertible subordinated notes, $41.0 million of debt under our Credit Facility and 23.7 million shares of common stock outstanding. Additionally, we had $10.8 million in cash and cash equivalents, which is sufficient to meet our short-term operating cash needs. If necessary, we currently have access to $359 million under our Credit Facility and are authorized to issue 100 million shares of common stock and 100 million shares of preferred stock. We believe that if needed we can access public markets to raise additional capital. We believe that our capital structure provides adequate funding to meet our growth objectives. We continuously evaluate our capital structure as it relates to our anticipated long-term funding needs. Changes to our capital structure may occur as a result of this analysis, or changes in market conditions.

### Off-Balance Sheet Arrangements

We have no off-balance sheet arrangements within the meaning of Item 303(a)(4) of Regulation S-K.

### Contractual Obligations

The following table summarizes our significant contractual obligations at September 28, 2012:

| CONTRACTUAL OBLIGATIONS | Payments due by period Total | Remainder of 2012 | 2013 - 2014 | 2015 - 2016 | After 2016 |
| --- | ---: | ---: | ---: | ---: | ---: |
| Debt obligations(a) | $282,010 | $1,335 | $233,472 | $44,769 | $2,434 |
| Operating lease obligations(b) | 19,174 | 1,072 | 8,311 | 6,658 | 3,133 |
| Purchase obligations(b) | 29,665 | 12,204 | 8,263 | 7,399 | 1,799 |
| Foreign currency contracts(b) | 14,550 | 2,550 | 12,000 | — | — |
| Pension obligations(c) | 10,861 | 193 | 10,668 | — | — |
| Total contractual obligations | $356,260 | $17,354 | $272,714 | $58,826 | $7,366 |

(a) Includes the annual interest expense on our convertible subordinated notes of 2.25%, which is paid semi-annually. Also includes $36.5 million of deferred federal and state taxes on the Company’s convertible subordinated notes that will be due if the notes are not converted before maturity. Amounts also include the expected interest expense on the $41.0 million outstanding on our line of credit based upon the period end weighted average interest rate of 2.17%. See Note 6 “Debt” of the Notes to Condensed Consolidated Financial Statements in this report for additional information.

\- 50 -

(b) See Note 11 “Commitments and Contingencies” of the Notes to Condensed Consolidated Financial Statements in this report for additional information about our operating leases, purchase obligations and foreign currency contracts.

(c) See Note 7 “Defined Benefit Plans” of the Notes to Condensed Consolidated Financial Statements in this report for additional information about our defined benefit plan obligations. As discussed in Note 9 “Other Operating (Income) Expense, Net,” in the third quarter of 2012, we finalized our plan to transfer most major functions currently performed at our facilities in Switzerland into existing facilities. As a result of this decision, we curtailed our defined benefit plan provided to employees at those facilities in the third quarter of 2012. As nearly all of the Swiss pension liability is expected to be paid off in the next year, the Company moved all Swiss pension plan investments into cash during the quarter. Plan assets are expected to be sufficient to cover plan liabilities.

This table does not reflect $0.8 million of unrecognized tax benefits as we are uncertain as to if or when such amounts may be settled. Refer to Note 10 “Income Taxes” of the Notes to Condensed Consolidated Financial Statements in this report for additional information about these unrecognized tax benefits.

We self-fund the medical insurance coverage provided to our U.S. based employees. Our risk is being limited through the use of stop loss insurance, which has an annual maximum aggregate loss of $13.5 million with a maximum benefit of $1.0 million. As of September 28, 2012, we have $2.0 million accrued related to our self-insured medical plan, which is recorded in Accrued Expenses in the Condensed Consolidated Balance Sheet, and is primarily based upon claim history. This table does not reflect any potential future payments for self-insured medical claims.

### Impact of Recently Issued Accounting Standards

In the normal course of business, we evaluate all new accounting pronouncements issued by the Financial Accounting Standards Board (“FASB”), Securities and Exchange Commission (“SEC”), Emerging Issues Task Force (“EITF”), American Institute of Certified Public Accountants (“AICPA”) or other authoritative accounting body to determine the potential impact they may have on our Condensed Consolidated Financial Statements. Based upon this review, we do not expect any of the recently issued accounting pronouncements, which have not already been adopted, to have a material impact on our Condensed Consolidated Financial Statements. See Note 16 “Impact of Recently Issued Accounting Standards” of the Notes to the Condensed Consolidated Financial Statements in this report for additional information.

### Forward-Looking Statements

Some of the statements contained in this report and other written and oral statements made from time to time by us and our representatives are not statements of historical or current fact. As such, they are “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. We have based these forward-looking statements on our current expectations, which are subject to known and unknown risks, uncertainties and assumptions. They include statements relating to:

- future sales, expenses and profitability;
- the future development and expected growth of our business and the markets we operate in;
- our ability to successfully execute our business model and our business strategy;
- our ability to identify trends within our markets and to offer products and services that meet the changing needs of those markets;
- our ability to design, develop, and commercialize complete medical devices;

\- 51 -

- projected capital expenditures; and
- trends in government regulation, including the impact of Health Care Reform.

You can identify forward-looking statements by terminology such as “may,” “will,” “should,” “could,” “expects,” “intends,” “plans,” “anticipates,” “believes,” “estimates,” “predicts,” “potential” or “continue” or the negative of these terms or other comparable terminology. These statements are only predictions. Actual events or results may differ materially from those suggested by these forward-looking statements. In evaluating these statements and our prospects generally, you should carefully consider the factors set forth below. All forward-looking statements attributable to us or persons acting on our behalf are expressly qualified in their entirety by these cautionary factors and to others contained throughout this report. We are under no duty to update any of the forward-looking statements after the date of this report or to conform these statements to actual results.

Although it is not possible to create a comprehensive list of all factors that may cause actual results to differ from the results expressed or implied by our forward-looking statements or that may affect our future results, some of these factors include the following: dependence upon a limited number of customers, product obsolescence, inability to market current or future products including complete medical devices, pricing pressure from and vertical integration by our customers, reliance on third party suppliers for raw materials, products and subcomponents, fluctuating operating results, inability to maintain high quality standards for our products, challenges to our intellectual property rights, product liability claims, inability to successfully consummate and integrate acquisitions, unsuccessful expansion into new markets, competition, inability to obtain licenses to key technology, regulatory changes or consolidation in the healthcare industry, and other risks and uncertainties that arise from time to time as described in the Company’s Annual Report on Form 10-K and other periodic filings with the SEC.

## Market risk

As filed, 5,305 characters.

***Foreign Currency –*** We have significant foreign operations in France, Mexico and Switzerland, which expose the Company to foreign currency exchange rate fluctuations due to transactions denominated in Euros, Mexican pesos and Swiss francs, respectively. We continuously evaluate our foreign currency risk and will take action from time to time in order to best mitigate these risks, which includes the use of various derivative instruments such as forward currency exchange contracts. A hypothetical 10% change in the value of the U.S. dollar in relation to our most significant foreign currency exposures would have had an impact of approximately $8 million on our annual sales. This amount is not indicative of the hypothetical net earnings impact due to partially offsetting impacts on cost of sales and operating expenses in those currencies. We estimate that foreign currency exchange rate fluctuations during the nine months ended September 28, 2012 decreased sales in comparison to the 2011 period by approximately $6 million.

In September 2011, we entered into two forward contracts to purchase 6.5 million and 4.9 million Mexican pesos per month beginning in January 2012 through December 2012 at an exchange rate of $0.0767 and $0.0713 per peso, respectively. These contracts were entered into in order to hedge the risk of peso-denominated payments associated with a portion of the operations at our Tijuana, Mexico facility for 2012 and are being accounted for as cash flow hedges.

In May 2012, we entered into two forward contracts to purchase 6.9 million and 7.2 million Mexican pesos per month beginning in January 2013 through December 2013 at an exchange rate of $0.0727 and $0.0693 per peso, respectively. These contracts were entered into in order to hedge the risk of peso-denominated payments associated with a portion of the operations at our Tijuana, Mexico facility for 2013 and are being accounted for as cash flow hedges.

\- 52 -

As of September 28, 2012, these contracts had a positive fair value of $0.9 million, which is recorded within Prepaid Expenses and Other Current Assets and Other Assets, in the Condensed Consolidated Balance Sheet. The amount recorded as a reduction of Cost of Sales during the nine months ended September 28, 2012 and nine months ended September 30, 2011 related to these forward contracts was $0.01 million and $0.5 million, respectively. No portion of the change in fair value of our foreign currency contracts during the nine months ended September 28, 2012 or September 30, 2011 was considered ineffective.

We translate all assets and liabilities of our foreign operations, where the U.S. dollar is not the functional currency, at the period-end exchange rate and translate sales and expenses at the average exchange rates in effect during the period. The net effect of these translation adjustments is recorded in the Condensed Consolidated Financial Statements as Comprehensive Income. The translation adjustment for the nine months ended September 28, 2012 was a $0.5 million loss. Translation adjustments are not adjusted for income taxes as they relate to permanent investments in our foreign subsidiaries. Net foreign currency transaction gains and losses included in Other (Income) Expense, Net amounted to a loss of $0.2 million for the nine months ended September 28, 2012. A hypothetical 10% change in the value of the U.S. dollar in relation to our most significant foreign currency net assets would have had an impact of approximately $8.5 million on our foreign net assets as of September 28, 2012.

***Interest Rates –*** Interest rates on our Credit Facility reset, at our option, based upon the prime rate or LIBOR rate, thus subjecting us to interest rate risk. To help offset this risk, from time to time, we enter into receive floating-pay fixed interest rate swaps indexed to the same applicable index rate as the debt it is hedging. In October 2012 we entered into a three-year $150 million interest rate swap, which amortizes $50 million per year. Under terms of the contract, we will receive a floating interest rate indexed to the one-month LIBOR rate and pay a fixed interest rate of 0.573%. The swap will be effective in February 2013. This swap was entered into in order to hedge against potential changes in cash flows on the anticipated outstanding debt on the Credit Facility from the repayment of our convertible subordinated notes, which is also expected to be in February 2013 and indexed to the one-month LIBOR rate. The receive variable leg of the interest rate swap and the variable rate paid on the debt is expected to have the same rate of interest, excluding the credit spread, and reset and pay interest on the same dates. This swap will be accounted for as a cash flow hedge.

As of September 28, 2012, we had $41.0 million outstanding on our revolving line of credit that is currently not being hedged. See Note 6 “Debt” of the Notes to Condensed Consolidated Financial Statements in this report for additional information about our outstanding debt. A hypothetical one percentage point (100 basis points) change in the prime rate on the $41.0 million of floating rate debt outstanding at September 28, 2012 would have an impact of approximately $0.4 million on our interest expense.

\- 53 -

## Controls and procedures

As filed, 2,778 characters.

a. Evaluation of Disclosure Controls and Procedures.

Our management, including the principal executive officer and principal financial officer, evaluated our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934) related to the recording, processing, summarization and reporting of information in our reports that we file with the SEC as of September 28, 2012. These disclosure controls and procedures have been designed to provide reasonable assurance that material information relating to us, including our subsidiaries, is made known to our management, including these officers, by other of our employees, and that this information is recorded, processed, summarized, evaluated and reported, as applicable, within the time periods specified in the SEC’s rules and forms. Based on their evaluation, as of September 28, 2012, our principal executive officer and principal financial officer have concluded that our disclosure controls and procedures are effective.

b. Changes in Internal Control Over Financial Reporting.

We completed the following acquisitions during 2011 and 2012:

- Micro Power Electronics, Inc. on December 15, 2011
- NeuroNexus Technologies, Inc. on February 16, 2012

We believe that the internal controls and procedures of the above mentioned acquisitions are reasonably likely to materially affect our internal control over financial reporting. We are currently in the process of incorporating the internal controls and procedures of these acquisitions into our internal controls over financial reporting.

The Company continues to extend its Section 404 compliance program under the Sarbanes-Oxley Act of 2002 (the “Act”) and the applicable rules and regulations under such Act to include these acquisitions. This included the conversion of the legacy ERP system of Micro Power in the third quarter of 2012 to the Oracle-based platform currently being utilized by other Greatbatch locations. The Company has excluded the 2011 acquisition listed above from management’s assessment of the effectiveness of internal control over financial reporting as of December 30, 2011, as permitted by the guidance issued by the Office of the Chief Accountant of the SEC. The Company will report on its assessment of the internal controls of its combined operations within the time period provided by the Act and the applicable SEC rules and regulations concerning business combinations.

There have been no changes in our internal control over financial reporting that occurred during our last fiscal quarter to which this Quarterly Report on Form 10-Q relates that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

\- 54 -

## Risk factors

As filed, 159 characters.

There have been no material changes from risk factors as previously disclosed in the Company’s Annual Report on Form 10-K for the year ended December 30, 2011.

Filed Nov 6, 2012.
Source: SEC EDGAR, the filing index for accession 0001193125-12-454418. Last ingested by Listed: Nov 11, 2026, 00:08 ET. No prices; not investment advice.
